Verona Pharma plc
VRNA
Rankning i aktier
#2231
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aktiekurs
$106.91
Senast synkroniserad: 2025-10-07
Marknadsvärde
$9.09B
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Kategori
Healthcare
Antal utestående aktier för Verona Pharma plc (VRNA)
Antal utestående aktier per June 2025: 85.64M
Enligt de senaste finansiella rapporterna och aktiekursen för Verona Pharma plc är det aktuella antalet utestående aktier 85.64M. I slutet av December 2023 hade företaget 75.51M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Verona Pharma plc (VRNA) från 2005 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 85.64M | 6.67% |
| 2024 | 80.29M | 6.32% |
| 2023 | 75.51M | 14.31% |
| 2022 | 66.06M | 11.68% |
| 2021 | 59.15M | 79.97% |
| 2020 | 32.87M | 149.64% |
| 2019 | 13.17M | 0.21% |
| 2018 | 13.14M | 19.79% |
| 2017 | 10.97M | 161.94% |
| 2016 | 4.19M | 65.85% |
| 2015 | 2.52M | 16.52% |
| 2014 | 2.17M | 154.03% |
| 2013 | 853.00K | 11.28% |
| 2012 | 766.55K | -0.19% |
| 2011 | 768.03K | 0.00% |
| 2010 | 768.03K | 0.00% |
| 2009 | 768.03K | 0.00% |
| 2008 | 768.03K | 0.00% |
| 2007 | 768.03K | 0.00% |
| 2006 | 768.03K | 0.00% |
| 2005 | 768.03K | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 196.46% |
US
|
|
| 396.00M | 362.37% |
US
|
|
| 478.91M | 459.18% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -27.39% |
NL
|
